La administración de melatonina no muestra efectos sobre la depresión y la ansiedad en la enfermedad de Parkinson: estudio piloto.

Delgado-Lara, Daniela L. C.; Ortiz, Genaro G.; González-Usigli, Héctor A.; González-Enríquez, G. Viviana; Chavarria-Avila, Efrain; Torres-Mendoza, Blanca M.

Background: Patients with Parkinson's disease (PD) usually present neuropsychiatric disorders, which are non-motor symptoms that diminish their quality of life such as depression and anxiety. Objective: To analyze the effect of the administration of melatonin (MEL) on the levels of depression and anxiety in patients with PD. Methods: A pilot study as a cross-controlled, randomized, double-blind, clinical trial was conducted in 26 patients with PD in stages 1-3 from Hoen and Yahr, who received 25 mg of MEL or placebo at noon and 30 min before bedtime for 3 months. Depression and anxiety were measured with Beck's Depression Questionnaire and Beck's Anxiety Questionnaire, respectively. Results: Seventy-three percent of the PD patients presented with depression, and 96% presented with anxiety, and after the intervention these percentages remained. Conclusion: At this dosage, MEL was found to lack effect on levels of depression and anxiety in PD patients. Further studies with longer administration periods and the use of different dosages are needed to evaluate the effects of MEL in PD.

DRUG therapy for Parkinson's disease; PILOT projects; STATISTICAL sampling; BLIND experiment; QUESTIONNAIRES; MELATONIN; ANXIETY; RANDOMIZED controlled trials; TREATMENT duration; TREATMENT effectiveness; DESCRIPTIVE statistics; DRUG efficacy; PSYCHOLOGICAL tests; MENTAL depression; EVALUATION

Archivos de Neurociencias, 2024, Vol 29, Issue 4, p139

1028-5938

Academic Journal

10.24875/ANC.M24000018